The medical devices sector is typified by frequent change and innovation, in response to problems and issues faced by the healthcare industry. As a result, the sector has seen the emergence of several start-up medtech companies offering disruptive, cutting-edge solutions. Most of these are private companies, where data such as revenue is frequently not disclosed. National estimates for Immudex sales in the US from 2017 to 2023, as well as year-on-year growth rates, can be viewed in GlobalData’s micro revenue report. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Immudex ApS, United States Revenue

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

Immudex ApS (Immudex) is a biotechnology company. Its primary activities involve research, development, and commercial operations focused on understanding the immune system to expand medical boundaries and open new therapeutic and diagnostic opportunities. Immudex offers a range of products including MHC I dextramer, MHC II dextramer, MR1 dextramer, CD1d dextramer, disease panels, SARS-CoV-2 dextramer reagents, and dextramer CMV Kit, among others. These products are developed using the company’s proprietary Dextramer technology. Immudex’s products and services are used in various applications such as cell therapy, vaccine development, antibody discovery, and TCR discovery across industries like immuno-oncology, infectious disease, autoimmunity, and transplantation. The company has distribution networks in Taiwan, Korea, Japan, Israel, and India. Immudex is headquartered in Copenhagen, Denmark. Key subsidiaries of Immudex include Immudex, Premas Life Sciences and Pharmigene.

The key metrics of Immudex related to marketed and pipeline products, ongoing clinical trials, active jobs and publications from 2023 are shown below:

As Immudex is a privately held company, it is not required to disclose its financial information and there is no stock listed on an exchange. GlobalData has access to a proprietary data set containing invoice data from over 2,600 healthcare institutions in the US and is therefore able to use estimations of a company’s revenue and growth to value private companies such as Immudex.

For a detailed understanding of the performance of Immudex, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s revenue report leverages GlobalData’s SKU tracker, which contains real-world, purchasing data from the US healthcare institutions.